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Abstract: A major current challenge in the treatment of advanced prostate cancer, which can be
initially controlled by medical or surgical castration, is the development of effective, safe, and
affordable therapies against progression of the disease to the stage of castration resistance. Here,
we showed that in LNCaP and 22Rv1 prostate cancer cells transiently overexpressing androgen
receptor splice variant-7 (AR-V7), nuclear factor-kappa B (NF-κB) was activated and could result
in up-regulated interleukin (IL)-6 gene expression, indicating a positive interaction between AR-V7
expression and activated NF-κB/IL-6 signaling in castration-resistant prostate cancer (CRPC)
pathogenesis. Importantly, both AR-V7-induced NF-κB activation and IL-6 gene transcription in
LNCaP and 22Rv1 cells could be inhibited by melatonin. Furthermore, stimulation of AR-V7 mRNA
expression in LNCaP cells by betulinic acid, a pharmacological NF-κB activator, was reduced by
melatonin treatment. Our data support the presence of bi-directional positive interactions between
AR-V7 expression and NF-κB activation in CRPC pathogenesis. Of note, melatonin, by inhibiting
NF-κB activation via the previously-reported MT1 receptor-mediated antiproliferative pathway,
can disrupt these bi-directional positive interactions between AR-V7 and NF-κB and thereby delay
the development of castration resistance in advanced prostate cancer. Apparently, this therapeutic
potential of melatonin in advanced prostate cancer/CRPC management is worth translation in the
clinic via combined androgen depletion and melatonin repletion.
Keywords: melatonin; androgen receptor splice variant-7; nuclear factor-kappa B; castration-resistant
prostate cancer
1. Introduction
Worldwide, prostate cancer is the fourth most common human cancer and the second most
common cancer in men [1]. Despite the detection of most clinical cases at an early localized stage
with prostate-specific antigen (PSA) screening, some patients still present late with more extensive
disease. Since androgen is recognized to be the most important growth-promoting hormone in prostate
cancer initiation and progression, androgen depletion therapy (ADT) in the form of medical or surgical
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castration to down-regulate androgen receptor (AR) signaling, is the recommended hormonal therapy
for advanced or metastatic prostate cancer palliation [2]. Given that patients receiving ADT will enter
an initial variable period of prostate cancer regression, and that the disease will relapse in the majority
of patients with castration-resistant prostate cancer (CRPC) development, there is a significant demand
for novel, effective, safe, and affordable therapies.
In the search for novel CRPC therapy, AR-mediated functions were noted to be incompletely
abrogated by ADT. While prostate cancer cells may evolve mechanisms to bypass AR signaling,
the growth of CRPC has in the majority of cases been shown to be dependent on sustained AR
signaling despite a castration level of testosterone. Importantly, advances in the understanding
of the mechanisms involved in CRPC pathogenesis, in particular aberrant AR signaling, have
led to the recent successful development of new AR-targeting therapies, such as abiraterone and
enzalutamide, to dampen sustained AR signaling in CRPC [3–6]. Of note, not all patients responded
to abiraterone or enzalutamide in clinical trials, and some initial responders eventually developed
progression of their disease [2–6]. Recently, androgen receptor splice variants (AR-Vs), which retain
the N-terminal transactivation domain and DNA binding domains, but lack the C-terminal ligand
binding domain (LBD) of AR [7–10], have been shown to be an important contributing factor for
resistance to abiraterone and enzalutamide. Among the different variants, AR-V7 is the most studied
member; its transcript abundance is high, and it is the only variant of which the encoded endogenous
protein was demonstrated [10,11]. AR-V7 is overexpressed in CRPC compared with benign prostate
or hormone-naïve prostate cancer tissue, and its expression has been associated with poor clinical
prognosis [7,8,12]. Whereas AR-V7 induces castration resistance in androgen-dependent prostate
cancer cell lines, knockdown of AR-V7 in CRPC cellular and xenograft models induces inhibition of
growth [7]. Given that AR-V7 expression increases in CRPC xenografts treated with enzalutamide or
abiraterone [13,14] and that detection of AR-V7 in circulating tumor cells from patients with CRPC
may be associated with resistance to enzalutamide or abiraterone [15], constitutively active AR-V7 and
related AR-Vs are likely to play a dominant role in inducing resistance to abiraterone and enzalutamide.
Instead of focusing on AR and AR-Vs, a different research approach has been adopted by our
laboratory in our search for novel CRPC therapy. We target the signaling pathway of melatonin, a
pineal gland neurohormone, for prostate cancer growth modulation. Initially, we demonstrated G
protein-coupled melatonin MT1 receptor expression in human prostate cancer tissues, and showed
the association of MT1 receptor expression with the antiproliferative action of melatonin in cellular
and animal models of prostate cancer [16–18]. In a subsequent proof-of-concept translational clinical
study, administration of melatonin to a castrated prostate cancer patient, whose prostate tumor
tissue predominantly expressed MT1 receptors, was found to slow the progression of the patient’s
relapsed CRPC [19]. Further laboratory studies enabled us to define the mechanisms underlying
melatonin-induced antiproliferation in advanced prostate cancer. These involve the dual actions of
MT1 receptor-mediated down-regulation of dihydrotestosterone (DHT)-activated AR signaling, and
inhibition of activated nuclear factor-kappa B (NF-κB) signaling in prostate cancer cells [20–23]. Based
on our data, we have recently proposed a novel combination therapeutic strategy of androgen depletion
and melatonin repletion for the treatment of advanced or metastatic prostate cancer [22,23]. Since
activation of NF-κB [24,25] and reactivation of AR signaling [26,27] are involved in prostate cancer
progression and CRPC development, we reason that androgen depletion and melatonin repletion
will help to prolong the progression-free survival of these patients by delaying CRPC development.
To gain further insights on how to fully exploit the therapeutic potential of melatonin in advanced
prostate cancer and CRPC management, the present study was conducted to investigate any functional
interactions among AR-V7, NF-κB, and melatonin in human prostate cancer cells.
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2. Results
2.1. Visualization of Overexpressed Enhanced Green Fluorescent Protein (EGFP)-Tagged AR and AR-V7 in
Prostate Cancer Cells
Figure 1 shows the fluorescence microscopic pictures of LNCaP and 22Rv1 cells transfected
with empty plasmid vector (pEGFP), plasmid encoding full-length AR (pEGFP-AR-FL), or plasmid
encoding AR-V7 (pEGFP-AR-V7). EGFP was observed in both the cytoplasm and nucleus of individual
prostate cancer cells transfected with the empty vector. While EGFP-AR-FL was found mainly in the
nucleus and with a relatively low level of expression in the cytoplasm of individual prostate cancer
cells transfected with pEGFP-AR-FL, expression of EGFP-AR-V7 was found predominantly in the
nucleus of individual prostate cancer cells transfected with pEGFP-AR-V7.
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To study the effects of AR-V7 on NF-κB, prostate cancer LNCaP and 22Rv1 cells were 
transfected with pEGFP, pEGFP-AR-FL, or pEGFP-AR-V7. As shown in Figure 2A,B, endogenous 
expression of full-length AR was detected in LNCaP and 22Rv1 cells using an AR antibody. 
Androgen receptor splice variants (AR-Vs) were also detected in 22Rv1, but not in LNCaP cells. The 
extra band in lane pEGFP-AR-FL and the extra band in lane pEGFP-AR-V7 detected in both LNCaP 
and 22Rv1 cells belong to the EGFP-tagged full-length AR and EGFP-tagged AR-V7, respectively 
(Figure 2A,B). When a specific antibody against AR-V7 was used, endogenous expression of AR-V7 
was detected in 22Rv1 cells but not in LNCaP cells. The expression of EGFP-tagged AR-V7 was 
detected in LNCaP and 22Rv1 cells transfected with pEGFP-AR-V7 plasmid (Figure 2C,D). 
Figure 1. Fluorescence microscopy of LNCaP and 22Rv1 cells transfected with empty plasmid vector
(pEGFP), plasmid encoding full-length androgen receptor (pEGFP-AR-FL), or plasmid encoding
androgen receptor splice variant-7 (pEGFP-AR-V7). The signals were observed under a fluorescence
microscope at 20×magnification. EGFP = enhanced green fluorescent protein.
2.2. Expression of AR and Its Variants (AR-Vs) in Prostate Cancer Cells
To study the effects of AR-V7 on NF-κB, prostate cancer LNCaP and 22Rv1 cells were transfected
with pEGFP, pEGFP-AR-FL, or pEGFP-AR-V7. As shown in Figure 2A,B, endogenous expression of
full-length AR was detected in LNCaP and 22Rv1 cells using an AR antibody. Androgen receptor
splice variants (AR-Vs) were also detected in 22Rv1, but not in LNCaP cells. The extra band in lane
pEGFP-AR-FL and the extra band in lane pEGFP-AR-V7 detected in both LNCaP and 22Rv1 cells
belong to the EGFP-tagged full-length AR and EGFP-tagged AR-V7, respectively (Figure 2A,B). When
a specific antibody against AR-V7 was used, endogenous expression of AR-V7 was detected in 22Rv1
cells but not in LNCaP cells. The expression of EGFP-tagged AR-V7 was detected in LNCaP and 22Rv1
cells transfected with pEGFP-AR-V7 plasmid (Figure 2C,D).
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Figure 2. Expression of full-length androgen receptor (AR) and its variants in transfected prostate cancer
cells. LNCaP (A) and 22Rv1 (B) cells were transfected with pEGFP, pEGFP-AR-FL, or pEGFP-AR-V7
expression plasmids. Immunoblot was carried out to detect the expression of endogenous and
recombinant AR and its variants. Antibody against an internal region of AR was used to detect
the expression of full-length AR (AR-FL) and its variants (AR-Vs). Cells transfected with pEGFP-AR-FL
or pEGFP-AR-V7 expression plasmids expressed EGFP-tagged AR-FL (EGFP-AR-FL) or EGFP-tagged
AR-V7 (EGFP-AR-V7), respectively. An antibody specifically against AR-V7 was also used to detect
endogenous AR-V7 (AR-V7) and EGFP-tagged AR-V7 (EGFP-AR-V7) in LNCaP (C) and 22Rv1 (D)
cells. β-actin was used as an internal control.
2.3. Effects of AR-V7 on NF-κB Activity
To investigate any functional interactions between AR-V7 and NF-κB, expression of the active
form of NF-κB in LNCaP and 22Rv1 cells, transfected with pEGFP-AR-FL or pEGFP-AR-V7, was
detected. As shown in Figure 3A,B, expression of the active form of NF-κB was elevated approximately
2.7-fold and 1.5-fold, by densitometry, in LNCaP and 22Rv1 cells overexpressing AR-V7, respectively,
compared with the pEGFP- or pEGFP-AR-FL-transfected cells. To demonstrate functional activation of
NF-κB by AR-V7, NF-κB activities in LNCaP and 22Rv1 cells transfected with plasmid pEGFP-AR-FL
or pEGFP-AR-V7 were measured by luciferase reporter assays. As shown in Figure 4, the NF-κB
reporter activities were elevated by 4.5-fold (p < 0.001) and 2.4-fold (p < 0.001), in LNCaP (Figure 4A)
and 22Rv1 cells (Figure 4B) transfected with pEGFP-AR-V7, respectively, compared to the empty
plasmid vector pEGFP-transfected cells. No up-regulation of NF-κB reporter activity was detected
in LNCaP and 22Rv1 cells transfected with pEGFP or pEGFP-AR-FL plasmids (Figure 4). These
results suggest that AR-V7 can activate NF-κB in prostate cancer cells. To further confirm NF-κB
activation by AR-V7, the expression of IL-6, a well-known downstream target gene of the transcription
factor NK-κB [28], was analyzed using quantitative polymerase chain reaction (Q-PCR). As shown
in Figure 5, IL-6 transcription was significantly up-regulated by 2-fold (p = 0.011) in LNCaP cells
(Figure 5A), and by 2.4-fold (p < 0.001) in 22Rv1 cells (Figure 5B) overexpressing AR-V7, as compared
to pEGFP-transfected cells.
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2.4. Inhibition of AR-V7 Induced IL-6 Gene Expression by Melatonin 
In light of our present results which showed that AR-V7 could activate NF-κB with resultant 
up-regulation of IL-6 and our previous data which showed inhibition of activated NF-κB signaling 
by melatonin in prostate cancer cells [23], we proceeded to test whether or not melatonin could 
inhibit the AR-V7-induced IL-6 gene expression in LNCaP and 22RV1 cells. In LNCaP cells, AR-V7 
up-regulated the expression of IL-6 by 2-fold (p = 0.011). However, the stimulatory effects of AR-V7 
on IL-6 expression could be significantly reduced by 10−6 M melatonin treatment (p = 0.039)  
(Figure 5A). It is noteworthy that in the presence of melatonin, AR-V7 could not up-regulate the 
expression of IL-6 (p = 0.393), indicating that melatonin could abrogate the increase in IL-6 gene 
expression induced by AR-V7 overexpression in LNCaP cells (Figure 5A). On the other hand, 
melatonin could significantly (p = 0.005) attenuate the AR-V7 induced 2.4-fold increase in IL-6 
expression (Figure 5B) in 22Rv1 cells transfected with pEGFP-AR-V7. 
Figure 3. Expression of active subunit of nuclear factor-kappa B (NF-κB) in transfected prostate cancer
cells. LNCaP (A) and 22Rv1 (B) cells were transfected with pEGFP, pEGFP-AR-FL, or pEGFP-AR-V7
expression plasmids. Immunoblot using an antibody against the active subunit of NF-κB was carried
out on protein lysates from transfected cells. β-actin was used as an internal control.
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Figure 4. NF-κB reporter activities in transfected prostate cancer cells. LNCaP (A) and 22Rv1 (B)
cells were transfected with pEGFP, pEGFP-AR-FL, or pEGFP-AR-V7 expression plasmids. Luciferase
reporter assay was used to measure NF-κB activities in those transfected cells. Cells transfected with
pEGFP were used as a control. Data are shown as relative luciferase activity (%) ± S.E.
2.4. Inhibition of AR-V7 Induced IL-6 Gene Expression by Melatonin
In light of our present results which showed that AR-V7 could activate NF-κB with resultant
up-regu ation of IL-6 and ou previous data which s owed inhibition of activated NF-κB signa ing
by melatonin in prost te cancer cells [23], we proceeded to test whether or not melatonin could
inhibit the AR-V7-induced IL-6 gene expression in LNCaP and 22RV1 cells. In LNCaP cells, AR-V7
up-regulated the expression of IL-6 by 2-fold (p = 0.011). However, the stimu atory effects of AR-V7 on
IL-6 expression could be g ificantly reduce by 1 −6 M melatonin treatment (p = 0.039) (Figure 5A).
It is noteworthy that in the presence of melatonin, AR-V7 could not up-regulate the expression of IL-6
(p = 0.393), indicati g that melatonin could abrogate the increase in IL 6 gene expression induced by
AR-V7 overexpression in LNCaP cells (Figure 5A). On the other h nd, m laton could significantly
(p = 0.005) atten ate the AR-V7 induced 2.4-fold increase in IL-6 expression (Figure 5B) in 22Rv1 cells
transfected with pEGFP-AR-V7.
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Figure 5. Q-PCR analysis of interleukin (IL)-6 expression in transfected prostate cancer cells. LNCaP
(A) and 22Rv1 (B) cells were transfected with pEGFP or pEGFP-AR-V7 expression plasmids, in the
presence or absence of melatonin (10−6 M) for 24 h. The relative levels of IL-6 were compared using
cells transfected with pEGFP as a control. Data are shown as relative fold-change of IL-6 mRNA
expression ± S.E.
2.5. Inhibition of NF-κB Induced AR-V7 Expression by Melatonin
It has been reported that activation of NF-κB could induce AR-V7 mRNA expression [29].
To confirm the above finding, betulinic acid, which is a NF-κB activator, was used to activate NF-κB,
and the expression level of AR-V7 was then measured by Q-PCR. To observe the induction of AR-V7
by activated NF-κB, LNCaP but not 22Rv1 cells were used because 22Rv1 cells are already expressing
highly elevated AR-V7 levels compared to LNCaP cells (Figure 2C,D). As shown in Figure 6, treatment
of LNCaP cells with 10−6 M betulinic acid significantly (p = 0.001) elevated the expression of AR-V7
by 3.5-fold, as compared to the DMSO-treated cells (control). Of note, the betulinic acid-stimulated
express on of AR-V7 coul be significantly reduced (p = 0.013) by o-incubation of the LNCaP cells
with 10−6 M melatonin.
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Figure 6. Q-PCR analysis of androgen receptor splice aria t-7 ( - 7) mRNA expression. LNCaP
cells were treated with 10 6 M melatonin, 10−6 M betulinic acid, 10−6 M melatonin plus 10−6 M
betulinic acid, or 0.001% dimethylsulfoxide (DMSO) for 48 h. The relative levels of AR-V7 were then
measured by Q-PCR and were compared to cells treated with DMSO as a control. Data are shown as
relative fold-change of AR-V7 mRNA expression ± S.E.
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2.6. Involvement of Membrane MT1 Receptor in Melatonin’s Inhibitory Effect on AR-V7-Induced
NF-κB Activation
While it has been recently reported by us that melatonin can inhibit the constitutively active
NF-κB via membrane G protein-coupled MT1 receptor in LNCaP and 22Rv1 prostate cancer
cells [23], we would like to confirm that the MT1 receptor is responsible for mediating the inhibitory
effect of melatonin on AR-V7 induced NF-κB activation observed in the present investigation.
LNCaP and 22Rv1 cells were transfected with pEGFP or pEGFP-AR-V7 expression plasmid. The
pEGFP-AR-V7-transfected cells were treated separately with 10−6 M melatonin, 10−6 M luzindole
(a melatonin receptor antagonist), or 10−6 M melatonin plus 10−6 M luzindole. After 48 h of treatment
with melatonin with or without luzindole, NF-κB activation in transfected cells was detected by
immunoblot. As shown in Figure 7, expression of active NF-κB was increased after LNCaP and 22Rv1
cells were transfected with pEGFP-AR-V7. Of note, the activating effects of AR-V7 on NF-κB were
blocked by 10−6 M melatonin. Furthermore, the inhibitory effects of melatonin on AR-V7-mediated
NF-κB activation could be blocked by 10−6 M luzindole. In separate experiments, LNCaP and 22Rv1
cells were transfected with pEGFP expression plasmid and after 48 h of treatment with or without
luzindole, NF-κB activation in transfected cells was detected by immunoblot. As shown in Figure S1,
no effects of luzindole on active NF-κB levels in LNCaP and 22Rv1 cells overexpressing the pEGFP
vector were observed. These results confirm that the observed inhibition of AR-V7 induced NF-κB
activation by melatonin in the present investigation is mediated via membrane MT1 receptor, which
has been shown by us previously to play an important role in transducing the antiproliferative action
of melatonin on prostate cancer cells [23].
Int. J. Mol. Sci. 2017, 18, 1130 7 of 13 
 
2.6. Involvement of Membrane MT1 Receptor in Melatonin’s Inhibitory Effect on AR-V7-Induced  
F-κB Activation 
hile it has been recently reported by us that melatonin can inhibit the constitutively active  
F-κB via e brane G protein-coupled MT1 receptor in LNCaP and 22Rv1 prostate cancer cells 
[23], we would like to confirm that the MT1 receptor is responsible for mediating the inhibitory effect 
of melatonin on AR-V7 induced NF-κB activation observed in the present investigation. LNCaP and 
22Rv1 cells were transfected with pEGFP or pEGFP-AR-V7 expression plasmid.  
The pEGFP-AR-V7-transfected cells were treated separately with 10−6 M melatonin, 10−6 M luzindole 
(a melatonin receptor antagonist), or 10−6  elatonin plus 10−6  luzindole. fter 48 h of treat ent 
with melatonin ith or without luzindole, F-κB activation in transfected cells as detected by 
i unoblot. As shown in Figure 7, expression of active NF-κB was increased after LNCaP and 
22Rv1 cells were transfected with pEGFP-AR-V7. Of note, the activating effects of AR-V7 on NF-κB 
were blocked by 10−6 M melatonin. Furthermore, the inhibitory effects of melatonin on 
AR-V7-mediated NF-κB activation could be blocked by 10−6 M luzindole. In separate experiments, 
LNCaP and 22Rv1 cells were transfected with pEGFP expression plasmid and after 48 h of treatment 
with or without luzindole, NF-κB activation in transfected cells was detected by immunoblot. As 
shown in Figure S1, no effects of luzindole on active NF-κB levels in LNCaP and 22Rv1 cells 
overexpressing the pEGFP vector were observed. These results confirm that the observed inhibition 
of AR-V7 induced NF-κB activation by melatonin in the present investigation is mediated via 
membrane MT1 receptor, which has been shown by us previously to play an important role in 
transducing the antiproliferative action of melatonin on prostate cancer cells [23]. 
 
Figure 7. Effects of melatonin with or without luzindole on the expression of active subunit of NF-κB 
in transfected prostate cancer cells. LNCaP (A) and 22Rv1 (B) cells were transfected with pEGFP, or 
pEGFP-AR-V7, in the presence or absence of 0.001% dimethylsulfoxide (DMSO), 10−6 M melatonin, 
10−6 M luzindole, or 10−6 M melatonin plus 10−6 M luzindole. Immunoblot using an antibody against 
the active subunit of NF-κB was carried out on protein lysates from transfected cells. β-actin was 
used as an internal control. 
3. Discussion 
Prostate cancer has become a major health problem of elderly men in the western world. Men 
with advanced or metastatic disease receive standard palliative castration or ADT [2]. Sadly, these 
patients inevitably succumb to their relapsed tumors after a variable period of disease remission. 
Recently approved drugs, abiraterone and enzalutamide, which further enhance androgen depletion 
by targeting the androgen receptor signaling pathway, are a welcomed breakthrough in the 
treatment of CRPC [3–6]. Like other effective anti-cancer drugs, the development of tumor resistance 
toward abiraterone or enzalutamide is a major concern and challenge to scientists and clinicians. 
Together, these create the demand for novel therapeutic strategies against advanced or metastatic 
prostate cancer as well as abiraterone-resistant or enzalutamide-resistant CRPC. 
It is worth noting that melatonin, which acts by inhibiting both activated AR and NF-κB 
signaling in prostate cancer cells, has been demonstrated to be a novel prostate growth inhibitor 
[22,23]. Given that constitutively active androgen receptor splice variants, in particular AR-V7, have 
been shown to confer resistance to abiraterone or enzalutamide [13,14], and that activation of NF-κB 
Figure 7. Effects of elatonin ith or ithout luzindole on the expression of active subunit of F-κB
in transfected prostate cancer cells. L CaP (A) and 22Rv1 (B) cells ere transfected ith pEGFP, or
pEGFP-AR-V7, in the presence or absence of 0.001% dimethylsulfoxide (DMSO), 10−6 melatonin,
10−6 M luzindole, or 10−6 M melatonin plus 10−6 M luzindole. Immunoblot using an antibody against
the active subunit of NF-κB was carried out on protein lysates from transfected cells. β-actin was used
as an internal control.
3. isc ssion
Prostate cancer has beco e a major health proble of elderly men in the western world. en
with advanced or metastatic disease receive standard palliative castration or A T [2]. Sa l , these
patients inevitably succ t their rela se t rs aft r a vari l ri f is r i i .
Recently approved drugs, abiraterone and enzaluta ide, hich further enhance androgen depletion
by targeting the androgen receptor signaling pathway, are a welcomed breakthrough in the treatment
of CRPC [3–6]. Like other eff ctiv anti- ancer drugs, the developm nt of tumor resistance toward
abiraterone or enzalutamide is major concern and hallenge to scientists and clinici s. Together,
these cr ate the dem nd for novel therapeutic strategies against advanced or metastatic pr stat cancer
as well as biraterone-resistant or enzalutamide-resistant CRPC.
It is worth noting that melatonin, which acts by inhibiti g oth activated AR an NF-κB signaling
in prostate cancer cells, has been demonstrate to be a novel prostate growth inhibito [22,23]. Given
Int. J. Mol. Sci. 2017, 18, 1130 8 of 13
that constitutively active androgen receptor splice variants, in particular AR-V7, have been shown
to confer resistance to abiraterone or enzalutamide [13,14], and that activation of NF-κB [24,25] and
reactivation of AR signaling [26,27] are involved in prostate cancer progression and CRPC development,
it would be of interest to investigate any interactions among AR-V7, NF-κB, and melatonin in prostate
cancer cells to gain further insights on the therapeutic potential of melatonin in advanced prostate
cancer and CRPC management.
In this study, we demonstrated that transient ectopic AR-V7 overexpression in LNCaP and 22Rv1
prostate cancer cells activate NF-κB with a resultant increase in IL-6 gene expression (Figures 3–5).
LNCaP and 22Rv1 cells were used in the present investigation because these two prostate cancer
cell lines have been previously shown by us to be responsive to melatonin receptor-mediated
antiproliferative actions [20–23]. Interestingly, melatonin, which has been shown by us to inhibit
constitutively active NF-κB in prostate cancer cells via the membrane G protein-coupled MT1
receptor [23], reduces both AR-V7-induced NF-κB activation and IL-6 gene transcription in LNCaP
and 22Rv1 cells (Figures 5 and 7). Given that IL-6 is an autocrine and paracrine growth factor involved
in CRPC development, prostate cancer metastasis and chemo-resistance of prostate cancer [28,30–33],
our results suggest that the effects of AR-V7 on CRPC development and prostate cancer progression
may be mediated in part via activation of NF-κB/IL-6 signaling in the tumor cells. Intrigued by
recent reports on increased AR-V7 expression in prostate cancer and epithelial cells as a result of
NF-κB activation [29,34], we have also tested whether melatonin can inhibit AR-V7 mRNA expression
induced by activation of NF-κB signaling in LNCaP cells. Importantly, treatment of LNCaP cells
with melatonin attenuates the betulinic acid-induced rise in AR-V7 mRNA expression (Figure 6).
Taken together, the data support the presence of bi-directional positive interactions between AR-V7
expression and NF-κB signaling in CRPC pathogenesis and suggest that melatonin may be of promise
as a potential therapeutic agent against AR-V7-mediated CRPC by serving as a NF-κB inhibitor. It
is worth noting that we have also attempted to study chronic AR-V7 overexpression in LNCaP cells,
which express a low endogenous AR-V7 transcript level [35]. Disappointingly, selected LNCaP cell
clones which had been stably-transfected with pEGFP-AR-V7 expression vector failed to grow under
our experimental conditions.
Based on the present results, we have updated our previously-reported melatonin MT1 receptor
antiproliferative pathway in prostate cancer [23] with bi-directional positive interactions between
AR-V7 and NF-κB/IL-6 signaling (Figure 8). Melatonin, by inhibiting NF-κB activation via the
previously-reported MT1 receptor-mediated antiproliferative pathway, can disrupt bi-directional
positive interactions between AR-V7 and NF-κB signaling, thereby possibly delaying the development
of castration resistance in advanced prostate cancer. Thus, melatonin, when used in combination
treatment with ADT, may provide additional therapeutic benefits in patients with advanced prostate
cancer or CRPC. Moreover, besides being a small molecule with an excellent pharmacological safety
profile, melatonin has been shown by a recent systematic review and meta-analysis of randomized trials
to significantly reduce asthenia, leucopenia, nausea and vomiting, hypotension, and thrombocytopenia
in cancer patients who are also receiving chemotherapy, radiotherapy, supportive therapy, or
palliative therapy [36]. We believe that this novel approach of combined androgen depletion and
melatonin repletion may improve both the survival and quality of life of patients suffering from
advanced prostate cancer or CRPC. Apparently, this therapeutic potential of melatonin, via combined
androgen depletion and melatonin repletion, is worth translation in the clinic for advanced prostate
cancer/CRPC management.
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growth inhibition of prostate cancer cells. → denotes activation (may involve multi-steps); a denotes
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AR, respectively, generated by alternative splicing of AR precursor mRNAs. Dotted line denotes
transcription or translation. Abbreviations: MLT, melatonin; PKC, protein kinase C; PKA, protein
kinase A; NF-κB, nuclear factor-kappa B; DHT, dihydrotestosterone; AR, androgen receptor; AR-FL,
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4. Materials and Methods
4.1. Cells, Plasmids, and Chemicals
Human prostate cancer cell lines LNCaP.FGC (CRL-1740) and 22Rv1 (CRL-2505) were purchased
from American Type Culture Collection (Manassas, VA, USA). LNCaP and 22Rv1 cells were grown
and maintained in Roswell Park Memorial Institute (RPMI) 1640 medium without phenol red
(Life Technologies, Inc., Grand Island, NY, USA) supplemented with L-glutamine and 10% fetal
bovine serum (FBS) (Life Technologies). To minimize the influence of hormones present in normal
FBS on our experiments, charcoal stripped FBS (Cat. No. F6765, Sigma-Aldrich, St. Louis, MO,
USA) was used in all experiments involving 22Rv1. However, normal FBS was used in LNCaP cells
whose growth was significantly compromised in charcoal stripped FBS. The expression plasmids which
contain full-length AR (pEGFP-AR-FL) and AR-V7 (pEGFP-AR-V7) were kindly provided by Dr. J. Luo
(Johns Hopkins University, Baltimore, MD, USA). The cDNAs encoding AR-V7 and full-length AR
were inserted into the pEGFP-C3 vector to express the EGFP-AR-V7 and EGFP-AR-FL fusion protein
respectively [8,37]. Melatonin (Cat. No. M5250) and luzindole (Cat. No. L2407) were purchased from
Sigma-Aldrich. Betulinic acid, which is a NF-κB activator, was obtained from Tocris (Bristol, UK).
4.2. Fluorescence Microscopy
LNCaP and 22Rv1 cells were grown in 12-well plates until 50–60% confluency. The cells were then
transfected with 0.5 µg of empty pEGFP vector, 0.5 µg of pEGFP-AR-FL, or 0.5 µg of pEGFP-AR-V7,
using FuGENE® HD Transfection Reagent (Cat. No. E231A; Promega, Madison, WI, USA). After 24 h
of incubation, any fluorescence signals from the recombinant EGFP or EGFP-tagged proteins in the
transfected cells were observed under a fluorescence microscope.
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4.3. Immunoblot Analysis
LNCaP and 22Rv1 cells were transfected with pEGFP, pEGFP-AR-FL, or pEGFP-AR-V7 for 24 h.
The cells were then lysed in SDS sample buffer, and the proteins were harvested for immunoblotting
as described previously [21]. Expression of AR and its variants were detected by a primary antibody
against AR (sc-7305, 1:2000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and a secondary
antibody against mouse immunoglobulin G (Cell Signaling Technology, Danvers, MA, USA). A specific
primary antibody against AR-V7 (AG10008, 1:2000 dilution; Precision Antibody, Columbia, MD,
USA) and a secondary antibody against mouse immunoglobulin G (Cell Signaling Technology) were
also used to detect the expression of AR-V7 in the transfected prostate cancer cells. In addition, the
detection of NF-κB activation in pEGFP-, pEGFP-AR-FL-, and pEGFP-AR-V7-transfected LNCaP and
22Rv1 cells were performed using a primary antibody against the active subunit of NF-κB (MAB3026,
1:2000 dilution; Millipore, CA, USA) and a secondary antibody against mouse immunoglobulin G (Cell
Signaling Technology). In separate sets of experiments, LNCaP and 22Rv1 cells were transfected with
pEGFP or pEGFP-AR-V7 in the presence or absence of 0.001% dimethylsulfoxide (DMSO), 10−6 M
melatonin, 10−6 M luzindole, or 10−6 M melatonin plus 10−6 M luzindole. After 48 h, activation of
NF-κB was detected using a primary antibody against the active subunit of NF-κB (Millipore) and a
secondary antibody against mouse immunoglobulin G (Cell Signaling Technology). The signals were
visualized by enhanced chemiluminescence Western blotting system (Bio-Rad, Hercules, CA, USA).
All blots were stripped in 25 mM glycine buffer (pH 2.0) for 30 min before re-probing with β-actin
(sc-5286, 1:5000 dilution; Santa Cruz Biotechnology).
4.4. Luciferase Reporter Assays
LNCaP and 22Rv1 cells (density 5 × 104/mL) were seeded in 24-well plates (n = 6). After 24 h,
the cells in each well were transfected with a mixture of 1.0 µL FuGENE® HD Transfection Reagent
(Promega, Madison, WI, USA), 0.2 µg NF-κB reporter plasmid pNF-κB-TA-Luc (Takara Bio Inc., Shiga,
Japan), 0.04 µg Renilla luciferase reporter pRL-tk (Promega), and 0.1 µg pEGFP, 0.1 µg pEGFP-AR-FL,
or 0.1 µg pEGFP-AR-V7. The NF-κB reporter activities were measured 24 h after transfection using the
Dual-Luciferase® Reporter Assay System (Promega). Both the firefly and Renilla luciferase activities
were measured according to the manufacturer’s instructions. The cells were washed three times with
phosphate-buffered saline. Passive lysis buffer was added to each well and was shaken at room
temperature for 15 min. Lysate (20 µL) from each sample was transferred to 96-well plate for firefly
and Renilla luciferase activity measurements by a luminometer [20].
4.5. Quantitative Polymerase Chain Reaction (Q-PCR)
LNCaP and 22Rv1 cells were seeded in 6-well plates. At 50–60% confluency, the cells were
transfected with 0.2 µg pEGFP or 0.2 µg pEGFP-AR-V7. After 24 h of transfection, the cells were
treated with 10−6 M melatonin or 0.001% DMSO as a control. Total RNA was extracted from the
cells and reversely transcribed into cDNAs after a further 24 h of incubation. The expression of
IL-6 was measured by Q-PCR, using a specific forward primer 5′-ATGCAATAACCACCCCTGAC-3′
and a specific reverse primer 5′-GAGGTGCCCATGCTACATTT-3′. In separate sets of experiments,
LNCaP cells reaching 50–60% confluency in 6-well plates were incubated with 10−6 M melatonin,
10−6 M betulinic acid, 10−6 M melatonin plus 10−6 M betulinic acid, or 0.001% dimethylsulfoxide
(DMSO) for 48 h, before the levels of endogenous AR-V7 were measured by Q-PCR, using
a specific forward primer 5′-CCATCTTGTCGTCTTCGGAAATGTTATGAAGC-3′ and a specific
reverse primer 5′-TTTGAATGAGGCAAGTCAGCCTTTCT-3′. Briefly, 4 µL of diluted cDNAs,
1 µL of forward/reverse primers, and 5 µL of 2× iTaq™ Universal SYBR® Green Supermix
(Bio-Rad) were added to form a 10 µL PCR reaction mixture. Q-PCR was performed using
MyiQ (Bio-Rad). The conditions were 95 ◦C for 5 min, followed by 40 cycles at 95 ◦C for 15 s
and 60 ◦C for 35 s. Relative quantities of specific RNAs were calculated using comparative CT
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method. The fold difference was normalized to endogenous β-actin, which was detected by Q-PCR
using a specific forward primer 5′-GGACTTCGAGCAAGAGATGG-3′ and a specific reverse primer
5′-AGCACTGTGTTGGCGTACAG-3′.
4.6. Statistical and Data Analyses
The data are presented as mean ± S.E. and analyzed by unpaired Student’s t test. The level of
significance for all statistical analyses was set at p < 0.05.
5. Conclusions
In this study, we demonstrated that melatonin inhibits AR-V7-induced NF-κB activation and
NF-κB activator-induced AR-V7 expression in prostate cancer cells. The data support the potential use
of melatonin in CRPC therapy.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/6/1130/s1.
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